Drug intelligence / Profile preview

B 002

Development stage: Phase 1
Lead developer: Shanghai Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

B 002 is a humanized monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2; also known as ERBB-2 or HER-2). It is designed to act as an antagonist of the ERBB 2 receptor and has potential antineoplastic (anti-cancer) activity. The drug is administered intravenously and was developed by Shanghai Pharmaceuticals Holding. Its primary indication under investigation has been HER2-positive breast cancer, particularly in metastatic disease settings for patients who have received at least one prior line of therapy[1][2].

Other names: Humanised anti-HER2 monoclonal antibody compound for injection - Shanghai Pharmaceuticals Holding

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on B 002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on B 002.

Explore the full profile